As another recent approach, vildagliptin, an oral anti-diabetic agent of the new dipeptidyl peptidase-4 inhibitor class of drugs, was reported by Moreira et al (12) to be an option for treatment of insulin resistance in cases with RMS. This evidence concerns the gene DPP4 and Insulin resistance.